Burlington, ON – April 13, 2004, The Jenex Corporation (“Jenex”) [TSXV: JEN], a company which developed its proprietary patented thermal therapeutic device for the prevention of cold sores, is now trading on the Berlin-Bremen Stock Exchange under the symbol JNX code number 694434.

Michael Jenkins, President and CEO of Jenex said, “Jenex is very pleased to be listed on the Berlin Exchange. With the planned launch of our cold sore device in late 2004 in Canada and the European markets throughout 2005, foreign investors will become informed of Jenex and its` cold sore prevention device. This listing will allow foreign investor’s easier access to participate in the public trading of Jenex common stock.

About The Jenex Corporation:

Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and the E.E.C protect the technology. The Corporation is preparing to launch its cold sore prevention device in the Canadian market in late 2004. Jenex has clearance to market the cold sore device in Canada with its approved claim, “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. Regulatory approvals are being pursued for USA, Europe and Australia. The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market.  More information about the Corporation can be found at http://www.jenexcorp.com.

For further information, please contact:

The Jenex Corporation
Michael Jenkins - President
Phone:  905-632-3830
Email:  jenex@sprint.ca
Fax:  905-632-3774
940 Sheldon Court, Suite 207
Burlington, Ontario Canada
L7L 5K6

          or

Investor Relations:
Current Capital Corporation 
John Robinson or Robert Kennedy
47 Avenue Road, Suite 200,
Toronto, ON M5R 2G3
416-860-0211 or 1-877-859-5200
JOHN@currentcapital.com  or Robert@currentcapital.com